About Axogen
Axogen is a company based in Alachua (United States) founded in 2002. It operates as a HealthTech. Axogen has raised $62.43 million across 11 funding rounds from investors including EW Healthcare Partners, Oberland Capital and PDL BioPharma. The company has 452 employees as of December 31, 2024. Axogen offers products and services including Avance Nerve Graft. Axogen operates in a competitive market with competitors including Humacyte, Avation, CUTISS, BioCircuit and Tissue Regenix, among others.
- Headquarter Alachua, United States
- Employees 452 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Axogen, Inc.
-
Annual Revenue
$187.34 M (USD)17.81as on Dec 31, 2024
-
Net Profit
-$9.96 M (USD)54.12as on Dec 31, 2024
-
EBITDA
$4.55 M (USD)128.6as on Dec 31, 2024
-
Total Equity Funding
$62.43 M (USD)
in 11 rounds
-
Latest Funding Round
$31 M (USD), Debt – Conventional
Oct 26, 2016
-
Investors
EW Healthcare Partners
& 9 more
-
Employee Count
452
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Axogen
Axogen is a publicly listed company on the NASDAQ with ticker symbol AXGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Axogen
Axogen offers a comprehensive portfolio of products and services, including Avance Nerve Graft.
Nerve graft used for peripheral nerve repair.
People of Axogen
Unlock access to complete
Sales and Marketing
107 people
Software Development Team
26 people
Leadership Team
11 people
Product Management Team
9 people
Operations Team
8 people
Senior Team
7 people
Human Resources and Administration
6 people
Staff Team
4 people
Unlock access to complete
Funding Insights of Axogen
Axogen has successfully raised a total of $62.43M across 11 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $31 million completed in October 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Axogen
Axogen has secured backing from 10 investors, including venture fund investors. Prominent investors backing the company include EW Healthcare Partners, Oberland Capital and PDL BioPharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Growth-stage healthcare companies are invested in by EW Healthcare Partners.
|
Locked | Locked | Locked | |
|
Structured financing solutions are provided for the global healthcare industry by Oberland Capital.
|
Locked | Locked | Locked | |
|
Biopharmaceutical company undergoing dissolution and asset distribution processes.
|
Locked | Locked | Locked |
Investor details for Axogen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Axogen
Investment portfolio details for Axogen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Axogen
Detailed financials for Axogen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Axogen Comparisons
Peer comparison for Axogen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Axogen
Axogen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Humacyte, Avation, CUTISS, BioCircuit and Tissue Regenix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Human tissue-based products are developed for vascular disease applications.
|
|
| Locked | Locked | Locked |
Wearable tibial nerve stimulation device treats overactive bladder symptoms.
|
|
| Locked | Locked | Locked |
Personalized skin tissue therapy is developed by CUTISS for surgeries.
|
|
| Locked | Locked | Locked |
Non-invasive electrophysiology devices are developed to monitor peripheral nerves.
|
|
| Locked | Locked | Locked |
Developer of regenerative medical devices by using cell technology
|
|
| Locked | Locked | Locked |
Medical devices for peripheral nerve injury treatment are provided.
|
Detailed competitors of Axogen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Axogen
Complete news archive for Axogen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Axogen
Axogen was founded in 2002 and raised its 1st funding round 5 years after it was founded.
Axogen is headquartered in Alachua, United States. It is registered at Alachua, Florida, United States.
Axogen is a funded company, having raised a total of $62.43M across 11 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Axogen is 452.
Annual revenue of Axogen is $187.34M as on Dec 31, 2024.
Axogen is dedicated to the development and delivery of technologies and solutions for peripheral nerve repair. The company operates in the healthcare sector, specifically targeting medical professionals and patients with nerve injuries. Solutions provided by Axogen aim to restore feeling and functionality to damaged nerves, improving quality of life. Products like Avance Nerve Graft are utilized to support nerve regeneration and recovery after traumatic injuries.
Axogen offers Avance Nerve Graft.
Yes, Axogen is publicly traded on NASDAQ under the ticker symbol AXGN.
Axogen has 10 investors. Key investors include EW Healthcare Partners, Oberland Capital, PDL BioPharma, JAM Capital Partners, and Cardinal Partners.
The ticker symbol of Axogen is AXGN on NASDAQ.